Absolute Neutrophil Count (ANC)
The absolute neutrophil count (ANC) is calculated by multiplying the total white blood cell count by the percentage of neutrophils (segmented neutrophils + bands), with normal values ranging from 1,500-8,000 cells/μL in Caucasian adults, though this varies by ethnicity.
Calculation Method
ANC = Total WBC count × (% segmented neutrophils + % bands) / 100
For example: If WBC = 4,000/μL and neutrophils = 50% (including bands), then ANC = 4,000 × 0.50 = 2,000/μL
Normal Ranges and Ethnic Variations
- Caucasian adults: Normal ANC ≥1,800 cells/μL (WHO definition) 1
- General adult population: Normal ANC ≥1,500 cells/μL 1, 2
- Infants (<1 year): Normal ANC ≥1,000 cells/μL 2
Important caveat: Normal ranges vary significantly by ethnicity and age. African and Middle Eastern populations commonly have lower baseline neutrophil counts (benign ethnic neutropenia), which should not be pathologized 1.
Classification of Neutropenia Severity
When ANC falls below normal thresholds 2, 3:
- Mild neutropenia: 1,000-1,500 cells/μL
- Moderate neutropenia: 500-999 cells/μL
- Severe neutropenia: <500 cells/μL
- Profound neutropenia: <100 cells/μL 4
Infection risk correlates directly with severity: Severe neutropenia (<500 cells/μL) substantially increases susceptibility to bacterial and fungal infections 1.
Clinical Definitions in Cancer Patients
Febrile neutropenia is defined as 4, 5:
- Single oral temperature ≥38.3°C (101°F) OR
- Sustained temperature ≥38.0°C (100.4°F) for ≥1 hour
- AND ANC <500 cells/μL (or <1,000 cells/μL with predicted decline to <500 cells/μL within 48 hours)
This is an oncologic emergency requiring antibiotic administration within 1 hour 5.
Management of Neutropenia
For Chronic Neutropenia (Non-Cancer)
- Confirm with repeat CBC with differential over 3+ months
- Examine peripheral blood smear
- Obtain bone marrow biopsy with cytogenetics if severe or unexplained
- Consider genetic testing for congenital causes (ELANE, HAX1, SBDS mutations)
- Test for autoimmune causes (antineutrophil antibodies) only when clinical context suggests autoimmunity
- Mild neutropenia (1,000-1,500 cells/μL): No treatment needed if asymptomatic; monitor clinically
- Moderate neutropenia (500-999 cells/μL): Consider G-CSF only if recurrent infections occur
- Severe neutropenia (<500 cells/μL):
- G-CSF (granulocyte colony-stimulating factor) is first-line therapy
- Aggressive treatment of bacterial/fungal infections with antibiotics
- Prophylactic antibiotics only in selected severe cases with recurrent infections 3
For Cancer Treatment-Related Neutropenia
Primary prophylaxis with G-CSF 7, 8:
- Indicated when chemotherapy regimen carries >20% risk of febrile neutropenia
- Start G-CSF 24-72 hours after last chemotherapy dose
- Continue until ANC recovery to >10,000 cells/μL (though achieving this high target is unnecessary)
- Dose: 5 μg/kg/day subcutaneously OR pegfilgrastim 6 mg as single dose 9
Management by ANC level in cancer patients 10:
- ANC >1,000 cells/μL but below normal: Individualize based on fever/infection presence; hold therapy temporarily if febrile
- ANC 501-1,000 cells/μL without fever: Hold cancer therapy temporarily; restart when count recovers
- ANC 501-1,000 cells/μL with fever: Hold therapy; restart at reduced dose after recovery
- ANC ≤500 cells/μL: Hold therapy; consider permanent discontinuation if persistent
Febrile neutropenia management 8, 4:
- Do NOT routinely use G-CSF for uncomplicated febrile neutropenia
- Consider G-CSF only in high-risk patients with:
- Expected prolonged neutropenia (≥10 days)
- Age ≥65 years
- Pneumonia, hypotension, or sepsis syndrome
- Invasive fungal infection
- Hospitalization at fever onset
Antibiotic Prophylaxis
For anticipated prolonged neutropenia (>7 days) 7, 4:
- Fluoroquinolone prophylaxis during neutropenic period
- Alternative: TMP/SMX or oral third-generation cephalosporin if fluoroquinolone-intolerant
For allogeneic stem cell transplant recipients 7:
- Penicillin prophylaxis starting 3 months post-transplant
- Continue until ≥1 year post-transplant or until immunosuppression discontinued in chronic GVHD patients
Critical Pitfalls to Avoid
- Do not use G-CSF during chest radiotherapy - increases complications and mortality 9
- Do not give G-CSF immediately before or during chemotherapy - risk of severe thrombocytopenia 9
- Do not misinterpret benign ethnic neutropenia as pathologic in African/Middle Eastern patients 1
- Do not delay antibiotics in febrile neutropenia - must start within 1 hour 5
- Do not continue empiric antibiotics until neutrophil recovery in stable afebrile patients without documented infection - can safely discontinue after 72 hours if clinically stable and afebrile for 48 hours 11